Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2025-08-25 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of Beijing SL Pharmaceutical Co., Ltd. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. It references relevant laws and regulations such as the Company Law and Securities Law of China. The content is a comprehensive governance document that sets out the internal rules and structure of the company rather than financial results, audit opinions, or meeting announcements. It is not an announcement or a report of a meeting, nor is it a financial report or legal proceeding update. Therefore, the document best fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-25 Chinese
北京双鹭药业股份有限公司内部审计制度
Audit Report / Information Classification · 95% confidence The document is titled '内部审计制度' which translates to 'Internal Audit System' or 'Internal Audit Policy' of Beijing Shuanglu Pharmaceutical Co., Ltd. It is a detailed internal audit policy document revised in August 2025. The content includes the structure, responsibilities, authority, procedures, and regulations of the internal audit function within the company. It references compliance with laws, regulations, and stock exchange rules, and outlines internal control and audit processes. It is not a financial report, earnings release, or announcement but a governance and procedural document related to internal audit and control. This fits best under the category of Audit Report / Information (AR) as it is a standalone audit-related document detailing audit principles and internal control oversight, not a full annual report or regulatory filing. The document length (9086 characters) and detailed content confirm it is the policy itself, not just an announcement or certification. FY 2025
2025-08-25 Chinese
北京双鹭药业股份有限公司累积投票制实施细则
Governance Information Classification · 95% confidence The document is titled '累计投票制实施细则' which translates to 'Cumulative Voting System Implementation Rules'. It details the rules and procedures for cumulative voting in the election of directors at shareholder meetings, including nomination, voting, and election processes. It references company law, stock exchange listing rules, and governance guidelines. The content is focused on governance practices related to board elections rather than financial results, audit, or other report types. It is a governance-related document outlining internal rules and procedures for board elections, which fits the category of Governance Information (CGR). The document length is 2566 characters, which is relatively short but contains substantive governance content, not just an announcement or summary. Therefore, the appropriate classification is Governance Information (CGR).
2025-08-25 Chinese
北京双鹭药业股份有限公司股东会议事规则
Governance Information Classification · 100% confidence The document is titled '股东会议事规则' which translates to 'Rules of Procedure for Shareholders' Meetings' for Beijing Shuanglu Pharmaceutical Co., Ltd. It details the governance structure, procedures for convening and conducting shareholders' meetings, voting rights, proposal submissions, and other procedural rules. It references relevant laws and regulations governing shareholder meetings and corporate governance. The document is a governance-related rulebook rather than a report of financial results, management changes, or meeting announcements. It is not an announcement or a report of voting results but a detailed governance document outlining internal rules and procedures for shareholder meetings. Therefore, the document fits best under the category of Governance Information (CGR).
2025-08-25 Chinese
北京双鹭药业股份有限公司公司内部财务管理制度
Governance Information Classification · 95% confidence The document is titled '双鹭药业内部财务管理制度' which translates to 'Beijing Shuanglu Pharmaceutical Co., Ltd. Internal Financial Management System'. It is a detailed internal policy document covering accounting standards, financial management, internal controls, asset management, financial reporting, and supervisory mechanisms. The content is focused on internal financial management rules and procedures rather than external financial results or disclosures. There is no indication that this is an annual report, audit report, earnings release, or any external regulatory filing. It is not a report publication announcement or a certification. The document is a comprehensive internal governance and control manual related to financial management. Therefore, the most appropriate classification is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including internal financial management systems.
2025-08-25 Chinese
北京双鹭药业股份有限公司风险投资管理制度
Governance Information Classification · 95% confidence The document is titled '风险投资管理制度' (Risk Investment Management System) and is issued by Beijing SL Pharmaceutical Co., Ltd. It is a detailed internal policy document outlining the principles, decision-making authority, management procedures, risk control measures, and disclosure obligations related to the company's risk investment activities. The document includes references to compliance with laws, regulatory bodies like the China Securities Regulatory Commission (CSRC) and Shenzhen Stock Exchange (SZSE), and internal governance structures. It is not a financial report, earnings release, or announcement but rather a governance and compliance policy document. It does not contain financial statements or results but focuses on internal rules and procedures. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3742 characters, which is substantial for a policy document but not a full financial report.
2025-08-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.